CPI-613 in Treating Patients With Myelodysplastic Syndromes Who Failed Previous Therapy | Aplastic Anemia and MDS International Foundation

Clinical Trial: NCT01902381

CPI-613 in Treating Patients With Myelodysplastic Syndromes Who Failed Previous Therapy
For more details on this clinical trial, including contact information, please see this trial’s listing on clinicaltrials.gov:
Purpose: 

This pilot clinical trial studies 6, 8-bis (benzylthio) octanoic acid (CPI-613) in treating patients withmyelodysplastic syndromes who failed previous therapy. Sometimes when chemotherapy or biological therapy is given, it does not stop the growth of tumor cells. The tumor is said to be resistant to treatment. 6, 8-bis (benzylthio) octanoic acid may interfere with the growth of tumor cells and may be an effective treatment formyelodysplastic syndromes that did not respond to previous therapy.

Status: 
Recruiting
Study Date: 
Thu, 08/01/2013 to Mon, 08/01/2016
Bone Marrow Disease(s): 
myelodysplastic syndromes (MDS)
Intervention: 
Drug: 6,8-bis(benzylthio)octanoic acid Given IV Other Names: alpha-lipoic acid analogue CPI-613 CPI-613